Redx Pharma PLC's (LON:REDX) Jane Robertson, Chief Medical Officer, talks to Proactive London about their lead cancer drug candidate RXC004.
Robertson explains their progress after coming to the end of the phase 1 monotherapy study which supports their belief that RXC004 has the potential to be a significant, novel targeted medicine for the treatment of Wnt-ligand driven cancer.
Redx is a biotech company focused on the discovery and development of novel targeted medicines for the treatment of cancer and fibrotic disease, aiming to progress them to clinical proof of concept (PoC).